Efficacy of Kangfuxin liquid for preventing and treating chemotherapy-induced oral mucositis: a systematic review and meta-analysis of randomized controlled trials DOI Creative Commons
Wei Sun, Jian Yang,

Xiaolin Feng

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 8, 2025

Chemotherapy-induced oral mucositis (CTOM) is a common side effect affecting 20%-40% of cancer patients receiving chemotherapy. Kangfuxin liquid (KFXL) has been used clinically to prevent and treat CTOM, but the evidence not systematically evaluated. This study aimed evaluate preventive therapeutic effects KFXL on CTOM. Nine electronic databases were searched identify KFXL-related randomized controlled trials (RCTs) for prevention treatment CTOM from inception September 2024. The primary outcomes incidence rate, efficacy rate cure secondary was healing time. Twenty-one involving 1825 included in this review. results our meta-analysis showed that, compared with basic care (BOC), significantly reduced severe (RR = 0.54, p < 0.00001; RR 0.23, 0.00001, respectively), improved 1.23, 0.0003; 1.99, 0.05, 2.06, 0.0004),and accelerated process (MD -2.48, 0.00001). However, other drugs have same treating 1.00, 0.99; 0.91, 0.39), time -0.01, 1.00). suggest that may provide more benefit BOC. Although be promising drug insufficient prove its superiority over guideline-recommended treatment. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024585859, ID: CRD42024585859.

Язык: Английский

Pharmacological targets and therapeutic mechanisms of Arabic gum in treating diabetic wounds: insights from network pharmacology and experimental validation DOI Creative Commons
Langjie Chai, Danyang Chen,

Lili Ye

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Фев. 20, 2025

On account of the long-term inflammatory microenvironment, diabetic wounds are challenging to heal in which advanced glycation end products considered important factors hindering healing wounds. Gum Arabic has demonstrated significant potential treatment various diseases owing its anti-inflammatory and antioxidant properties. Nonetheless, there is still insufficient research on role gum facilitating mechanisms. This study aims investigate pharmacological targets therapeutic mechanisms wound by adopting network pharmacology, molecular docking, experimental validation. Key active components disease were identified through pharmacology bioinformatics. GO/KEGG enrichment was performed identify critical pathways. Cytoscape AutoDock used for prediction docking In vitro, Transwell assay tube formation evaluate effect human fibroblasts migration umbilical vein endothelial cells angiogenesis. Western blotting analyzed Pro-caspase-1, ASC, NLRP3 NF-κB pathway-related proteins. vivo, a full-thickness model established. Histological changes assessed via H&E Masson's staining, oxidative stress levels DHE inflammation with IL-1β, CD68 CD206 angiogenesis cell proliferation CD31 Ki67 staining. The proteins Phospho-NF-κB P65 Network analysis key targets, encompassing HSP90AA1, STAT3, PRKCB, involved AGEs-NF-κB-NLRP3 signaling axis. Molecular strong binding affinity between AG these targets. lessened AGEs-induced activation inflammasome modulation pathway reinforced AG-treated exhibited accelerated healing, augmented collagen deposition, lowered inflammation, strengthened promotes modulating axis, exerting anti-inflammatory, antioxidant, pro-angiogenic, cell-proliferative effects. provides new insights into repair suggests that promising agent improving healing.

Язык: Английский

Процитировано

0

Efficacy of Kangfuxin liquid for preventing and treating chemotherapy-induced oral mucositis: a systematic review and meta-analysis of randomized controlled trials DOI Creative Commons
Wei Sun, Jian Yang,

Xiaolin Feng

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 8, 2025

Chemotherapy-induced oral mucositis (CTOM) is a common side effect affecting 20%-40% of cancer patients receiving chemotherapy. Kangfuxin liquid (KFXL) has been used clinically to prevent and treat CTOM, but the evidence not systematically evaluated. This study aimed evaluate preventive therapeutic effects KFXL on CTOM. Nine electronic databases were searched identify KFXL-related randomized controlled trials (RCTs) for prevention treatment CTOM from inception September 2024. The primary outcomes incidence rate, efficacy rate cure secondary was healing time. Twenty-one involving 1825 included in this review. results our meta-analysis showed that, compared with basic care (BOC), significantly reduced severe (RR = 0.54, p < 0.00001; RR 0.23, 0.00001, respectively), improved 1.23, 0.0003; 1.99, 0.05, 2.06, 0.0004),and accelerated process (MD -2.48, 0.00001). However, other drugs have same treating 1.00, 0.99; 0.91, 0.39), time -0.01, 1.00). suggest that may provide more benefit BOC. Although be promising drug insufficient prove its superiority over guideline-recommended treatment. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024585859, ID: CRD42024585859.

Язык: Английский

Процитировано

0